CJC-1295
CJC-1295 (with DAC)
Long-acting growth hormone pulse amplification
How it works
CJC-1295 binds and stimulates GHRH receptors on the pituitary gland, amplifying the natural pulsatile release of growth hormone. The DAC (Drug Affinity Complex) modification extends its half-life from minutes to days.
What the research explores
In published research, CJC-1295 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.
- Significantly increases basal GH and IGF-1 levels
- Promotes lean muscle mass development
- Accelerates fat metabolism and lipolysis
- Improves sleep quality and recovery
- Enhances connective tissue strength
- Supports bone mineral density
CJC-1295 demonstrated dose-dependent increases in mean plasma GH concentrations of 2-10 fold in clinical trials, with effects sustained for 6+ days per administration.
Adverse events & gaps
Well-tolerated in trials. Potential for water retention, insulin resistance at high doses, and administration-site reactions.
Stay Informed on
Peptide Research
Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.
No spam. Unsubscribe at any time.